Trial Profile
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs COVID-19 vaccine (Primary) ; Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms CoVPN3008; UBUNTU
- 06 Mar 2024 Results assessing the safety of mRNA-1273, the effectiveness of hybrid versus vaccine immunity, and SARS-CoV-2 viral persistence among people with HIV, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 13 Nov 2023 Planned End Date changed from 24 Apr 2024 to 12 Apr 2024.
- 13 Nov 2023 Planned primary completion date changed from 15 Oct 2023 to 12 Apr 2024.